Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 12/20 | 0.66 |
| ▸ | LCK | P06239 | 12/20 | 0.66 |
| ▸ | LYN | P07948 | 11/20 | 0.66 |
| ▸ | SRC | P12931 | 11/20 | 0.66 |
| ▸ | INSR | P06213 | 10/20 | 0.66 |
| ▸ | HCK | P08631 | 10/20 | 0.66 |
| ▸ | BRAF | P15056 | 7/20 | 0.56 |
| ▸ | TEK | Q02763 | 1/20 | 0.53 |
| ▸ | RAF1 | P04049 | 1/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3588959 | 0.93 | LCK (0.59) | KDRLCKLYNSRCINSR | |
| SCHEMBL9967393 | 0.91 | INSR (0.57) | KDRLCKLYNSRCINSR | |
| SCHEMBL3827237 | 0.90 | KDR (0.66) | KDRLCKLYNSRCINSR | |
| SCHEMBL3584384 | 0.87 | LCK (0.66) | KDRLCKLYNSRCINSR | |
| SCHEMBL3822873 | 0.86 | KDR (0.66) | KDRLCKLYNSRCINSR | |
| SCHEMBL3827627 | 0.85 | KDR (0.59) | KDRLCKLYNSRCINSR | |
| SCHEMBL3589391 | 0.85 | KDR (0.59) | KDRLCKLYNSRCINSR | |
| SCHEMBL3821636 | 0.85 | LCK (0.66) | KDRLCKLYNSRCINSR | |
| SCHEMBL9967394 | 0.84 | MAPK14 (0.53) | KDRLCKLYNSRCINSR | |
| SCHEMBL3829904 | 0.84 | KDR (0.65) | KDRLCKLYNSRCINSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8202876-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2012-06-19 | — | — | US | claimed |
| US-20100029605-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2010-02-04 | — | — | US | claimed |
| US-8202876-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2012-06-19 | — | — | US | disclosed |
| US-20100029605-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2010-02-04 | — | — | US | disclosed |
| WO-2008042639-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029605-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | FYN, ABL2, LCK | KDR 13/4885LCK 3/4885LYN 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.